FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.